News Zai Lab Limited Mexican S.E.

Equities

ZLAB N

US98887Q1040

End-of-day quote Mexican S.E. Other stock markets 03:30:00 07/05/2024 am IST			5-day change	1st Jan Change
273 ^MXN	+0.74%		-.--%	-46.71%

27/06	Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	MT
20/06	Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	28/06	MT
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath	22/06	PU
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	20/06	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading	14/06	MT
Transcript : Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM	12/06
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024	12/06	CI
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D	12/06	BU
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	04/06	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	24/05	MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	22/05	MT
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05	BU
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05	CI
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21/05	AQ
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	20/05	MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20/05	MT
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05	BU
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05	CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	16/05	MT
Zai Lab Announces Participation in May and June Investor Conferences	16/05	BU
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	14/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zai Lab Limited Mexican S.E.

Equities

ZLAB N

US98887Q1040

Summary

Filters